skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

ジェネリック医薬品、バイオシミラーの情報源として

Generics_Bulletin2

日本国内では2020年9月までにジェネリック医薬品の使用割合を80%にする目標を挙げています。このような中、Generics Bulletinはグローバルな専門アナリスト&ジャーナリストの広範なネットワークを駆使して、世界中の市場動向を追跡することで、貴重なニュースを提供しています。また、市場プレーヤーのトップエグゼクティブやオピニオンリーダーのインタビューなども定期的に掲載しています。

深い専門性と具体的なデータに基づいたニュースレポートは、世界の大手ジェネリック医薬品メーカーの戦略を明らかにし、その計画、ポートフォリオ、業績を分析&報告します。

Generics Bulletinでは以下のトピックをカバーしています。

  • 規制・コンプライアンスの変更
  • 法規制の進展
  • 競合製品の開発
  • 合併・買収活動
  • 新製品の発売
  • マーケティングの課題
  • 広告戦略など

このサービスの特徴

無料の最新記事&レポート

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Indian Leaders Begin Unique Collaboration On Molnupiravir

    GB2106_India_COVID_2E96KD7_1200

    Major Indian pharmaceutical companies including Cipla, Dr Reddy’s, Emcure, Sun and Torrent have entered into a first-of-its-kind collaboration to jointly sponsor, supervise and monitor the clinical trial of the investigational oral anti-viral drug molnupiravir to fight against COVID-19 in India. 

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Aspen Faces Vaccine Setback In South Africa As Strides Explores Oral COVID Treatment

    GB2106_COVID_2CAG8G3_1200

    After a production setback, Aspen and Johnson & Johnson announce a donation of 300,000 vaccines to South African teachers. Strides partners with Ennaid for an oral COVID drug, while Dr Reddy’s, Lupin, Cipla and Sun Pharma Partner with Eli Lilly for baricitinib in India and Formycon receives approval for early action for its COVID-19 drug.

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Overseas API Manufacturing Identified As Key Vulnerability In US Supply Chain

    GB2106_Biden_Harris_2CD06C5_1200

    After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    New COVID-19 Vaccine Patent Database Launched

    PS2106_Database_E0GPRM_1200

    As part of its drive to maximize global access to coronavirus vaccines, the Medicines Patent Pool has developed a publicly accessible resource giving information on the patent status of approved and candidate vaccines.

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Celltrion Opens Up Canadian Market For Remsima SC

    GB2106_Canada_Open_Door_Flag_DYRCJR_1200

    Celltrion has pushed into another new market with its Remsima SC subcutaneous version of infliximab, launching the innovative biosimilar in Canada.

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Industry Steps Up To Help India Through Second Wave

    GB2104_India_flag_covid_2CF9PDG_1200

    As India sees a consistent rise in daily cases and deaths due to COVID-19, the off-patent industry is stepping up to make drugs affordable and available. Zydus Cadila is seeking approval for virafin, while Natco has applied for molnupiravir approval. Vaccine production and availability has also come under focus. 

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    European Biosimilars Can Benefit From Sharing Experiences

    GB2104_Europe_Connections_Map_Space_2A9CJEX_1200

    Attendees to Medicines for Europe’s virtual summit on biosimilars heard how learning from experiences across Europe can allow individual countries to build a toolbox of policies to help create a sustainable biosimilars market.

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    FDA Guides On Generic Development During COVID-19

    GB2104_COVID_questions_1686525004_1200

    Guidance published by the US FDA in the form of a question-and-answer document addresses questions from ANDA applicants about generic drug development during the COVID-19 pandemic.

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Pfizer Breaks With Biosimilars In China Through WuXi Bio Deal

    China_globe_1200x675

    Pfizer has announced plans to put a lid on its biosimilars programs in China, while agreeing the sale of its manufacturing site in Hangzhou.

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    FDA Guides On Bioequivalence Studies And COVID-19

    USFDAentrancesignwithblueskybehindit_1200

    Guidance on protecting participants in bioequivalence studies during the COVID-19 pandemic has been published by the FDA.

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    EU Reforms Must Heed Pandemic Lessons

    Covid19 Eu reforms

    Reforms set out by the European Commission to better prepare the EU for future health crises must heed key lessons learned from experiences of the COVID-19 pandemic, such as the benefits of digitalization, Medicines for Europe has urged.

    Topic Coronavirus EU Policy & Regulation

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Glenmark Debuts Favipiravir For COVID-19 In India

    Glenmark has received the go-ahead in India for and launched its low-priced favipiravir product for mild to moderate COVID-19 under an accelerated approval process.

    Topic Coronavirus drug-review

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Generics Industry Experiences Extraordinary First Quarter Due To COVID-19 Crisis

    Coronavirus-induced stockpiling and advanced prescribing of medicines has resulted in generics companies across the world registering unprecedented growth during the first quarter of 2020. However, many companies predict sales will level off again in the next quarter and beyond. And as demand fluctuates following the COVID-19 outbreak, companies have started taking precautionary measures to avoid supply-chain disruptions.

    Topic Coronavirus

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    EU Sees Drug Shortage Risk From COVID-19 Second Wave

    A second wave of COVID-19 infection later this year would put even greater pressure on drugs used in patients hospitalized with serious respiratory problems, a new report warns.

    Topic Coronavirus Distribution

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    European Industry Played Key Role In Mitigating COVID-19

    In the first part of an exclusive two-part interview, James Burt – Accord’s executive vice-president for Europe, the Middle East and North Africa – talks to Generics Bulletin about the key actions taken by the generics industry to mitigate the coronavirus pandemic, and the changed landscape that the off-patent arena can expect to see in future.

    Topic Coronavirus Manufacturing

医薬品産業専門のジャーナリスト&アナリスト

Editor

Aidan Fry

Editor, Executive Editor, Commercial/R&D

UK

Aidan Fry

Aidan specializes in

  • Biosimilars
  • Generics
  • Legal Issues And Intellectual Property
  • Market intelligence

+22 year(s) experience

無料トライアル&お問い合わせ

ニュースサービスでは無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

新型コロナウイルス感染拡大防止のため在宅勤務を実施しています。お問い合わせの際は下記のフォームまたはメールアドレスをご利用下さい。

Eメール:inquiry.jp@informa.com


オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。